Literature DB >> 33656852

Simple and Sensitive Method for Deep Profiling of Host Cell Proteins in Therapeutic Antibodies by Combining Ultra-Low Trypsin Concentration Digestion, Long Chromatographic Gradients, and BoxCar Mass Spectrometry Acquisition.

Song Nie1, Tyler Greer1, Reid O'Brien Johnson1, Xiaojing Zheng1, Albert Torri1, Ning Li1.   

Abstract

Liquid chromatography coupled to mass spectrometry (LC-MS) is a powerful tool for the analysis of host cell proteins (HCP) during antibody drug process development due to its sensitivity, selectivity, and adaptability. However, the enormous dynamic range between the therapeutic antibody and accompanying HCPs poses a significant challenge for LC-MS based detection of these low abundance impurities. To address this challenge, enrichment of HCPs via immunoaffinity, protein A, 2D-LC, or other strategies is typically performed. However, these enrichments are time-consuming and sometimes require a large quantity of sample. Here, we report a simple and sensitive strategy to analyze HCPs in therapeutic antibody samples without cumbersome enrichment by combining an ultra-low trypsin concentration during digestion under nondenaturing conditions, a long chromatographic gradient, and BoxCar acquisition (ULTLB) on a quadrupole-Orbitrap mass spectrometer. Application of this strategy to the NIST monoclonal antibody standard (NISTmAb) resulted in the identification of 453 mouse HCPs, which is a significant increase in the number of identified HCPs without enrichment compared to previous reports. Known amounts of HCPs were spiked into the purified antibody drug substance, demonstrating that the method sensitivity is as low as 0.5 ppm. Thus, the ULTLB method represents a sensitive and simple platform for deep profiling of HCPs in antibodies.

Entities:  

Year:  2021        PMID: 33656852     DOI: 10.1021/acs.analchem.0c03931

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  2 in total

Review 1.  The measurement and control of high-risk host cell proteins for polysorbate degradation in biologics formulation.

Authors:  Xuanwen Li; Fengqiang Wang; Hong Li; Douglas D Richardson; David J Roush
Journal:  Antib Ther       Date:  2022-01-15

2.  Host cell protein profiling of commercial therapeutic protein drugs as a benchmark for monoclonal antibody-based therapeutic protein development.

Authors:  Rosalynn Molden; Mengqi Hu; Sook Yen E; Diana Saggese; James Reilly; John Mattila; Haibo Qiu; Gang Chen; Hanne Bak; Ning Li
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.